Delivery Order SPE2DR25D3012-SPE2DR26F4C2M
Award Date 11/24/25
Potential Completion Date 11/25/25
Potential Value $94K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $18,474.88 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens (2 mL vials). This firm fixed-price, non-competitive delivery order was awarded on November 17, 2025, with an ultimate completion date of November 18, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic immunosuppressant medication commonly used to...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $11,981.84 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pens on October 29, 2025. This non-competitive delivery order, classified as firm fixed price, is set to be completed by October 30, 2025, with performance originating from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent is a biologic medication used to treat conditions including atopic dermatitis, asthma, and...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $25,857.34 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pens on November 20, 2025, with an ultimate completion date of November 21, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The pharmaceutical product will be delivered to the company's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Dupixent (dupilumab) 300 mg/2 mL pens totaling $11,987.86 on November 25, 2025, with completion targeted for November 26, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December...
- The Defense Logistics Agency (DLA) awarded a $41,691.55 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Dupixent 300 mg/2 ml pens. This competitive award, which carries no set-aside designation, is scheduled for completion by August 29, 2025, with performance taking place at the contractor's corporate office in Conshohocken, Pennsylvania. Dupixent is a biologic medication used to treat various inflammatory and allergic conditions, including...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $74,194.57 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pens on July 22, 2025, with an ultimate completion date of July 23, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and specifies performance at the vendor's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat various allergic and...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $17,219.89 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on July 25, 2025. This is a firm fixed price, non-set-aside contract with an ultimate completion date of July 28, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication commonly used to treat moderate-to-severe atopic dermatitis, asthma, and...
- The Defense Logistics Agency awarded a delivery order valued at approximately $247,722 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 mL pens on September 19, 2025, with an ultimate completion date of September 22, 2025. This competitively awarded, firm fixed-price delivery order utilizes no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic immunosuppressant medication commonly used to treat...
- The Defense Logistics Agency awarded a $60,018.63 firm fixed price delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 mL pens. This non-competitive, competitively awarded delivery order is scheduled for completion by September 23, 2025, and will be performed at the vendor's corporate headquarters in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a prescription biologic medication used to treat moderate-to-severe atopic dermatitis, eosinophilic esophagitis, and...
- The Defense Logistics Agency awarded a delivery order valued at $37,021.94 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on August 28, 2025, with an ultimate completion date of August 29, 2025. This competitively awarded, firm fixed-price contract with no set-aside designation will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat atopic dermatitis, asthma, and other...